Ovarian Cancer | Topics

Secondary Cytoreduction Followed by Chemotherapy May Improve PFS in Ovarian Cancer
April 09, 2021

The phase 3 SOC-1 trial found an association between secondary cytoreduction followed by chemotherapy and prolonged progression-free survival when compared with chemotherapy alone for patients with relapsed ovarian cancer.

Long-Term OS Data for Olaparib Maintenance in Ovarian Cancer Show Clinically Meaningful Boost
April 05, 2021

With more than 5 years of follow-up, results from the SOLO2 trial of olaparib maintenance in relapsed, high-grade serous or endometrioid ovarian cancer, including primary peritoneal or fallopian tube cancer, were reported and showed superiority of the agent over placebo.

Ovarian Cancer: Frontline Therapy
April 01, 2021

Dr. Rebecca Previs from the Duke Cancer Center reviews frontline therapy options for patients with advanced ovarian cancer.